Veterinary Vaccines Market Insights, Competitive Landscape and, Market Forecast - 2027

Veterinary Vaccines Market Insights, Competitive Landscape and, Market Forecast - 2027

VETERINARY VACCINES MARKET BY TYPE (INACTIVATED VETERINARY VACCINES , LIVE-ATTENUATED VETERINARY VACCINES , SUBUNIT VETERINARY VACCINES, RECOMBINANT VETERINARY VACCINES, AND VIRAL VECTOR VETERINARY VACCINES), BY INDICATION (VIRAL, BACTERIAL, AND OTHERS), BY ANIMAL GROUP (POULTRY, LIVESTOCK, COMPANION ANIMALS, AND OTHERS), BY END-USER (VETERINARY CLINICS AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST TILL 2027 OWING TO INCREASING INCIDENCES OF ZOONOTIC DISEASES AND GROWING FOCUS ON REGULAR IMMUNIZATION SCHEDULE OF ANIMALS

The global veterinary vaccines market was valued to be USD 9.78 billion, and will grow at a CAGR of 9.13% during the forecast period from 2022 to 2027 in order to reach USD 16.47 billion by 2027. The veterinary vaccines market is witnessing a positive market growth owing to the factors such as increasing incidences of zoonotic diseases, rising concern over antimicrobial resistance in animals, rising demand for safe and efficient food production, among others. Moreover, the growing focus on reducing animal morbidity and mortality rates due to preventable diseases in animals through regular immunization is another prominent factor leading to appreciable revenue growth in the veterinary vaccines market during the forecast period (2022-2027).

VETERINARY VACCINES MARKET DYNAMICS:

One of the key aspects driving the veterinary vaccines market is the rising incidences of zoonotic diseases such as Rabies, ZIKV virus, Ebola virus, and SARS-CoV among others.

Rabies, a highly contagious and fatal zoonotic disease affecting dogs, cats, foxes, humans, and other animals is one of the major factor responsible for the growth of veterinary vaccines market. As per American Veterinary Medical Association 2020 data, around 4,500 cases of rabies among animals were reported in 2020 in the US.

According to World Health Organization 2021, every year more than 29 million people worldwide receive a post-bite rabies vaccination. Also, as per the same source, globally, the total economic burden of dog-mediated rabies annually is estimated at USD 8.6 billion. The 99% cases of human rabies are from the bite of rabies infected dog. Thus necessitating the immunization of dogs against rabies to prevent serious consequences, positively impacting the veterinary vaccines market.

Nobivac® Rabies is inactivated vaccine for dogs, cats, cattle, sheep, goats, horses against Rabies.

Moreover, the increasing concern on antimicrobial resistance owing to over-use and misuse of antibiotics in veterinary medicine is likely to increase the demand for veterinary vaccines. The vaccines against antimicrobial-resistant pathogens not only prevent the animal from dangerous life threating diseases but also reduce the use of antibiotics, thereby lowering down the chances of development of antimicrobial resistance in animals. The risk of transmission of antimicrobial resistance to humans via animal food products is another major concern that can be tackled with the use of vaccines in animals against multiple antimicrobial resistance pathogens.

The continuous rise in government awareness programs on importance of animal vaccines is another factor playing essential part in increasing the demand for veterinary vaccines. For example, in 2019, government of India launched National Animal Disease Control Programme (NADCP) under which 100% of cattle, buffalo, sheep, goat and pig population will be vaccinated for Foot & Mouth Disease and 100% bovine female calves of 4-8 months of age for brucellosis with the aim of controlling both Foot & Mouth Disease and Brucellosis.

However, lack of awareness and access to veterinary vaccines and stringent government regulations for veterinary vaccines may prove to be challenging factors for veterinary vaccines market growth.

The veterinary vaccines market was slightly impacted during the period of COVID- 19 pandemic owing to the implementation of measures to curb the spread of the COVID-19 infection. The COVID- 19 pandemic led to lockdown implementation and border closures across the globe leading to halt in manufacturing and supply of veterinary vaccines. Also, the import and export of veterinary vaccines was majorly affected. However, with the resumption of activities across industries including the healthcare sector, there has been rising demand for the veterinary vaccines owing to resumption of suspended animal immunization schedules. The post COVID scenario is going to be uplifting for the veterinary vaccines market during the forecast period from 2022-2027.

VETERINARY VACCINES MARKET SEGMENT ANALYSIS:

Veterinary Vaccines Market by Type (Inactivated Veterinary Vaccines, Live-Attenuated Veterinary Vaccines, Subunit Veterinary Vaccines, Recombinant Veterinary Vaccines, and Viral Vector Veterinary Vaccines), Indication (Viral, Bacterial, and Others), Animal Group (Poultry, Livestock, Companion Animals, and Others), End-Users (Veterinary Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the veterinary vaccines market, the viral vector category is estimated to grow at a CAGR of xx during the forecast period from 2022 to 2027 to reach USD xx million by 2027. This can be attributed to advantages associated with viral vectored veterinary vaccines.

The viral vectors such as adenovirus, herpesvirus and poxviruses are majorly employed in the production of veterinary vaccines.

The viral vectored animal vaccines have number of benefits over conventional vaccine types such as they are safer, stable, and are efficient even in the absence of an adjuvant. They do not usually lead to any kind of adverse reaction in animals and can be adjusted to meet the growing disease challenges.

In case of certain serious animal diseases, viral vectored veterinary vaccines are more effective and good option over other vaccine types available. For example, animals such sheep, goat, and others can be protected against Rift Valley fever virus (RVFV) with a single dose administration of recombinant adenovirus RVFV vaccine.

Also, the bypassing of maternal immunity has been evident for recombinant adenovirus vaccines such as against herpes virus which causes Aujeszky's disease in pigs.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. For example, In May 2021, Boehringer Ingelheim launched poultry viral vector vaccine named VAXXITEK® HVT+IBD in India. The vaccine provide immunity to chickens, namely broiler, layer and breeder against three diseases including Marek's Disease (MD), Infectious Bursal Disease (IBD) and Newcastle disease (ND)

Therefore, owing to the advantages and applications associated with viral vectored veterinary vaccines, the product category is expected to witness a considerable growth eventually contributing to the overall growth of the global veterinary vaccines market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL VETERINARY VACCINES MARKET:

Among all the regions, North America is estimated to grow at a CAGR of xx during the forecast period from 2022 to 2027 to reach USD xx million by 2027. This can be ascribed to the increasing prevalence of animal diseases such as rabies and others, high disposable income, sophisticated veterinary healthcare infrastructure, and presence of key players in the region among others.

One of the key supporting factors for the growth of the North America Veterinary Vaccines Market is the increasing prevalence of rabies among animals in the United States. As per the figures mentioned by the Texas Department of State Health Services 2021, there were around 455 cases of rabies reported in Texas in 2021. According to New Jersey Department of Health 2021 data, around 257 cases of rabies were reported positive in 2020 in New Jersey. As per the California Department of Public Health 2021 statistics, around 220 cases of animal rabies were reported in 2020 in California.

Another aspect stimulating the growth of the United States veterinary vaccines market is the large number of pet owners in the country as companion animals are required to be routinely vaccinated in order to avoid serious consequences from diseases. According to APPA National Pet Owners Survey 2021-2022, around 70% of the US household that is around 90.5 million homes own a pet in the US. As per the same source around 69.0 million households are dog owners and approx 45.3 million households are cat owners. Dogs are required to be annually administered with vaccines against number of deadly diseases such as rabies, Coronavirus, Parvovirus, and others.

Therefore, the large number of pet owners and prevalence of animal diseases in the region is expected to contribute in the growth of the veterinary vaccines market in the United States. Thus, propelling the growth of North America region market.

VETERINARY VACCINES MARKET KEY PLAYERS:

Some of the key market players operating in the veterinary vaccines market includes Hester Biosciences Limited, Boehringer Ingelheim International GmbH, Zoetis Services LLC, Elanco, Merck & Co., Inc., Indian Immunologicals Ltd., Phibro Animal Health Corporation, Biogénesis Bagó®, HIPRA, ARKO, Kyoto Biken Laboratories, Inc., Vaxxinova® International BV, Dyntec s. r. o., Brilliant Bio Pharma, BioTestLab, Virbac, KBNP, BIMEDA, Shchelkovo biocombinat, VAKSINDO ANIMAL HEALTH PVT. LTD, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN VETERINARY VACCINES MARKET:

In September 2022, Boehringer Ingelheim launched Fencovis® which is the first vaccine against calf disease.

In June 2022, India's first homegrown COVID-19 vaccine Anocovax for animals, produced by the ICAR-National Research Centre on Equines (NRCE) was launched in India.

In April 2022, Ceva Animal Health launched IBird vaccine against Infectious Bronchitis in India.

KEY TAKEAWAYS FROM THE VETERINARY VACCINES MARKET REPORT STUDY

Market size analysis for current veterinary vaccines market size (2020), and market forecast for 5 years (2021-2027)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the veterinary vaccines market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global veterinary vaccines market.

Various opportunities available for the other competitor in the veterinary vaccines market space.

What are the top performing segments in 2020? How these segments will perform in 2027.

Which is the top-performing regions and countries in the current veterinary vaccines market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for veterinary vaccines market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS VETERINARY VACCINES MARKET REPORT STUDY

Veterinary Vaccines products providers

Research organizations and consulting companies

Veterinary Vaccines -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in veterinary vaccines

Various end users who want to know more about the veterinary vaccines market and latest technological developments in the veterinary vaccines market.

FREQUENTLY ASKED QUESTIONS FOR VETERINARY VACCINES MARKET:

1. What is Veterinary Vaccines?

Veterinary vaccines are preparations that contain a weakened or killed form of pathogen or their part or any other form such that it is no longer virulent (ability to cause disease) in order to imbibe active immunity in a animal in which it is administered by triggering the adaptive immune response.

2. What is the global market for Veterinary Vaccines?

The global veterinary vaccines market was valued to be USD 9.78 billion, and will grow at a CAGR of 9.13% during the forecast period from 2022 to 2027 in order to reach USD 16.47 billion by 2027.

3. What are the drivers for Global Veterinary Vaccines Market?

The veterinary vaccines market is witnessing a positive market growth owing to the factors such as rising prevalence of multiple animal diseases such as rabies, food & mouth disease, coronavirus, and others that are contributing in the growing demand for veterinary vaccines. Moreover, the growing focus on reducing animal morbidity and mortality rates due to preventable diseases in animals is another prominent factor responsible for the growth of the veterinary vaccines market. Additionally, the rising concern over antimicrobial resistance in animals is creating an exigency for the veterinary vaccines.

4. Who are the key players operating in the global veterinary vaccines market?

Some of the key market players operating in the Veterinary Vaccines Market includes Hester Biosciences Limited, Boehringer Ingelheim International GmbH, Zoetis Services LLC, Elanco, Merck & Co., Inc., Indian Immunologicals Ltd., Phibro Animal Health Corporation, Biogénesis Bagó®, HIPRA, ARKO, Kyoto Biken Laboratories, Inc., Vaxxinova® International BV, Dyntec s. r. o., Brilliant Bio Pharma , BioTestLab, Virbac, KBNP, BIMEDA, Shchelkovo biocombinat, VAKSINDO ANIMAL HEALTH PVT. LTD, and others.

5. Which region has the highest share in Veterinary Vaccines Market?

Among all the regions, North America is estimated to amass the significant revenue share in the global veterinary vaccines market. This can be ascribed to the increasing prevalence of animal diseases, and large number of pet owners in the region, particularly in the United States. Furthermore, high disposable income, sophisticated veterinary healthcare infrastructure, and presence of key market players in the region is another factor that acts as a supportive factor for the North America veterinary vaccines market growth.

Please Note: It will take 3-5 business days to complete the report upon order confirmation.